A cautionary tale illustrates how forging a deal with a Big Pharma can have unexpected and far-reaching tax consequences.

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGSNet product sales of FILSPARI ...

As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval- ...

GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.

Amicus is focused on delivering significant long-term revenue growth and anticipates surpassing $1 billion in total sales in 2028. The Company anticipates continuing to grow its current commercial ...

As of February 17, 2025, 1,028 unique patient prescriptions for Attruby have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

Q4 2024 Earnings Call Transcript February 18, 2025 Tactile Systems Technology, Inc. beats earnings expectations. Reported EPS ...

CRA International, Inc. ( NASDAQ: CRAI) Q4 2024 Earnings Conference Call February 20, 2025 10:00 AM ET Paul Maleh - Chairman, President, CEO Daniel Mahoney - EVP, CFO and Treasurer Chad Holmes - EVP ...

Expect to see Medicare grow slightly more expensive following last year’s unusual price drop. In January 2024, most U.S.